8.04
Aurinia Pharmaceuticals Inc stock is traded at $8.04, with a volume of 1.47M.
It is down -3.02% in the last 24 hours and up +1.13% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$8.29
Open:
$8.2
24h Volume:
1.47M
Relative Volume:
1.11
Market Cap:
$1.11B
Revenue:
$175.51M
Net Income/Loss:
$-78.02M
P/E Ratio:
-15.17
EPS:
-0.53
Net Cash Flow:
$-34.18M
1W Performance:
-5.74%
1M Performance:
+1.13%
6M Performance:
+9.69%
1Y Performance:
+60.48%
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
AUPH
Aurinia Pharmaceuticals Inc
|
8.04 | 1.11B | 175.51M | -78.02M | -34.18M | -0.53 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
Jun-17-20 | Initiated | BTIG Research | Buy |
May-05-20 | Initiated | Cowen | Outperform |
Jan-10-20 | Initiated | Jefferies | Buy |
Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
May-18-17 | Reiterated | H.C. Wainwright | Buy |
Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
Mar-22-17 | Reiterated | FBR & Co. | Outperform |
Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
Jun-30-16 | Initiated | H.C. Wainwright | Buy |
May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March - Insider Monkey
(AUPH) Trading Signals - Stock Traders Daily
Aurinia Pharmaceuticals Announces Financial Growth and Pipeline Progress in 2024 - Zenopa
Principal Financial Group Inc. Sells 1,325 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet - MSN
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome - MarketScreener
Aurinia Pharmaceuticals’ chief medical officer sells shares worth $68,350 - Investing.com India
Aurinia Pharmaceuticals’ chief medical officer sells shares worth $68,350 By Investing.com - Investing.com UK
Commit To Purchase Aurinia Pharmaceuticals At $7, Earn 17.4% Annualized Using Options - Nasdaq
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting Point - Yahoo Finance
Aurinia Pharmaceuticals stock climbs on insider buying - MSN
Aurinia Pharmaceuticals CFO Joseph Miller sells shares worth $939,611 - Investing.com Australia
Aurinia Pharmaceuticals COO Donley sells shares worth $994,424 By Investing.com - Investing.com Canada
Aurinia Pharmaceuticals CEO Peter Greenleaf sells shares worth $2.87 million - Investing.com India
Aurinia Pharmaceuticals CFO Joseph Miller sells shares worth $939,611 By Investing.com - Investing.com South Africa
Major Investment Alert: Kevin Tang Boosts Stake in Aurinia Pharmaceuticals - TipRanks
Aurinia Pharmaceuticals’ chief medical officer sells $97,912 in stock - Investing.com
Aurinia Pharmaceuticals COO Donley sells shares worth $994,424 - Investing.com India
Aurinia Pharmaceuticals EVP Stephen Robertson sells shares worth $975,223 - Investing.com
Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? - Nasdaq
Objective long/short (AUPH) Report - Stock Traders Daily
LAWSUITS FILED AGAINST ABBV, SDIG and AUPHJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Atria Wealth Solutions Inc. Buys Shares of 15,000 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Results: Aurinia Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Simply Wall St
Results: Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Canada Finance
IFP Advisors Inc Raises Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Sees Strong Trading Volume Following Strong Earnings - MarketBeat
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2024 Earnings Call Transcript - Insider Monkey
Aurinia Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Regulatory and Financial Challenges Loom for Aurinia Pharmaceuticals Despite FDA and EC Approvals - TipRanks
Aurinia Pharmaceuticals Reports Strong 2024 Financial Growth - TipRanks
Aurinia Pharmaceuticals Reports Balanced Earnings with Growth and Challenges - TipRanks
Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations - Benzinga
Aurinia: Q4 Earnings Snapshot - CT Insider
Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates - MSN
Earnings call transcript: Aurinia Pharmaceuticals Q4 2024 misses EPS forecast - Investing.com
Aurinia Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aurinia Pharmaceuticals Swings to Q4 Earnings, Revenue Rises -February 27, 2025 at 09:26 am EST - Marketscreener.com
Aurinia Pharmaceuticals Reports Strong Financial Growth in 2024 - TipRanks
Aurinia Pharmaceuticals Files Form 8-K Indicating Key Corporate Event - TipRanks
Earnings Flash (AUPH) Aurinia Pharmaceuticals Reports Q4 Revenue $59.9M, vs. FactSet Est of $60.1M - Marketscreener.com
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q4 EPS $0.01, vs. FactSet Est of $0.02 Loss - Marketscreener.com
Aurinia Pharmaceuticals Inc. SEC 10-K Report - TradingView
Aurinia Pharma earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress - Business Wire
High Growth Tech Stocks In The United States Spotlighting Three Leaders - Yahoo Finance
Is Aurinia Pharmaceuticals Inc. (AUPH) the Best Small-Cap Growth Stock to Buy Now? - Insider Monkey
10 Best Small-Cap Growth Stocks to Buy Now - Insider Monkey
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):